SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Dise

LCTX

Related stories